Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notification of Major Interest in Shares

10 Jan 2018 16:31

RNS Number : 5295B
Evgen Pharma PLC
10 January 2018
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Evgen Pharma PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Seneca Partners Limited

4. Full name of shareholder(s)  (if different from 3.):iv

Share Nominees Limited

WCS Nominees Limited

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

2 January 2018

6. Date on which issuer notified:

10 January 2018

7. Threshold(s) that is/are crossed orreached: vi, vii

5%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

3,536,022

3,536,022

6,872,726

6,872,726

7.37%

GB00BSVYN304

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

6,872,726

7.37%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Seneca Partners Limited

15. Contact telephone number:

01942 271 746

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLBLGDBLDBBGIG
Date   Source Headline
28th Mar 20197:00 amRNSPoster presentation of Imperial College data
25th Mar 20197:00 amRNSSFX-01 meets primary endpoints in STEM trial
18th Mar 20192:01 pmRNSPrice Monitoring Extension
18th Mar 20197:00 amRNSUpdate on SFX-01 trial read-out dates
5th Mar 20197:00 amRNSSFX-01 data published in peer reviewed journal
6th Feb 20193:30 pmRNSHolding(s) in Company
5th Feb 20197:00 amRNSClinical trial update confirms read-outs on track
30th Jan 20195:28 pmRNSGrant of Options
23rd Jan 20197:00 amRNSSFX-01 featured in Nature Reviews Drug Discovery
22nd Jan 20197:00 amRNSChange of Adviser
19th Dec 20186:02 pmRNSShare option exercise and issue of equity
12th Dec 20187:00 amRNSInterim Results
10th Dec 20183:00 pmRNSNominated Adviser Status
4th Dec 20187:00 amRNSPoster Presentation of SFX-01 and Trial Update
3rd Dec 20187:00 amRNSNotification of Half Year Results
19th Nov 20187:00 amRNSInvestor Presentation in Manchester
8th Nov 20187:00 amRNSDirectorate Changes
23rd Oct 20189:57 amRNSHolding(s) in Company
18th Oct 20187:00 amRNSPlacing
18th Sep 20187:00 amRNSInvestor Symposium
11th Sep 20187:00 amRNSNotice of Investor Symposium
26th Jul 20183:22 pmRNSResult of AGM
26th Jul 20187:00 amRNSAGM Statement
25th Jul 20187:00 amRNSFinal Patient Recruited in STEM Phase IIa Trial
10th Jul 201811:00 amRNSGrant of share options, issue of equity and TVR
29th Jun 201810:45 amEQSHardman & Co Research: Evgen Pharma (EVG): 2018, a pivotal year
21st Jun 201812:30 pmRNSPosting of Annual Report and AGM Notice
13th Jun 20182:15 pmEQSHardman & Co Research: Evgen Pharma (EVG): Encouraging interim data from the STEM trial
13th Jun 20187:00 amRNSFull Year Results
11th Jun 20189:05 amRNSSecond Price Monitoring Extn
11th Jun 20189:00 amRNSPrice Monitoring Extension
11th Jun 20187:00 amRNSInterim Update on STEM Trial
7th Jun 20184:40 pmRNSSecond Price Monitoring Extn
7th Jun 20184:35 pmRNSPrice Monitoring Extension
30th May 20187:00 amRNSNotification of Preliminary Results
15th May 201811:00 amRNSPrice Monitoring Extension
14th May 20187:00 amRNSUpcoming Investor Presentations
2nd May 20187:00 amRNSGrant of further European patent
26th Apr 20184:40 pmRNSSecond Price Monitoring Extn
26th Apr 20184:35 pmRNSPrice Monitoring Extension
24th Apr 20187:00 amRNSPresentation at World Orphan Drug Congress USA
20th Mar 20187:00 amRNSResearch Collaboration with Imperial College
5th Mar 20187:00 amRNSUpdate on Novel Sulforaphane Analogues
15th Jan 20187:00 amRNSPoster Presentation of SFX-01 Mechanistic Data
10th Jan 20184:31 pmRNSNotification of Major Interest in Shares
5th Jan 20189:49 amRNSNotification of Major Interest in Shares
5th Jan 20189:48 amRNSNotification of Major Interest in Shares
2nd Jan 20185:44 pmRNSTotal Voting Rights
28th Dec 201711:49 amRNSResult of General Meeting
22nd Dec 201710:10 amRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.